Disarming suppressor cells to improve immunotherapy

Cancer Immunology, Immunotherapy

Volumn 61, Issue 2, 2012, Pages 283-288

  Whiteside, Theresa L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Adenosine; CITIM2011; Ectonucleotidases; Prostaglandin E 2; T effector cells; Treg

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE; CD39 ANTIGEN; CELL PROTEIN; CYCLIC AMP; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; PROTEIN TR1; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CONCENTRATION RESPONSE; EFFECTOR CELL; ENZYME REGULATION; HUMAN; HYDROLYSIS; IMMUNE DEFICIENCY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

5'-NUCLEOTIDASE; ADENOSINE MONOPHOSPHATE; ANIMALS; DINOPROSTONE; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84856759921     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1171-7     Document Type: Review

References (27)

1. RK Gershon 1975 A disquisition on suppressor T cells Transpl Rev 26 170 185 1:STN:280:DyaE28%2FjsVGksg%3D%3D
2. M Czystowska L Strauss C Bergmann M Szajnik H Rabinowich TL Whiteside 2010 Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2) J Mol Med 88 577 588 20225066 10.1007/s00109-010-0602-9 1:CAS:528:DC%2BC3cXmtVyrtrY%3D
3. + responder cells by Fas-mediated apoptosis J Immunol 182 1469 1480 19155494 1:CAS:528:DC%2BD1MXnsVersQ%3D%3D
4. EM Shevach 2009 Mechanisms of Foxp3+ T regulatory cell-mediated suppression Immunity 30 636 645 19464986 10.1016/j.immuni.2009.04.010 1:CAS:528:DC%2BD1MXosVCks7g%3D
5. MV Sitkovsky J Kjaergaard D Lukashev A Ohta 2008 Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia Clin Cancer Res 14 5947 5952 18829471 10.1158/1078-0432.CCR-08-0229 1:CAS:528:DC%2BD1cXhtF2nur3F
6. G Raimondi MS Turner AW Thomson PA Morel 2007 Naturally occurring regulatory T cells: recent insights in health and disease Crit Rev Immunol 27 61 95 17430097 1:CAS:528:DC%2BD2sXptVSltb4%3D (Pubitemid 46659048)
7. MG Roncarolo S Gregori M Battaglia R Bacchetta K Fleischhauer MK Levings 2006 Interleukin-10 secreting type 1 regulatory T cells in rodents and humans Immunol Rev 212 28 50 16903904 10.1111/j.0105-2896.2006.00420.x 1:CAS:528:DC%2BD28XpvFegtr4%3D (Pubitemid 44116698)
8. C Bergmann L Strauss R Zeidler S Lang TL Whiteside 2007 Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma Cancer Res 67 8865 8873 17875728 10.1158/0008-5472.CAN-07-0767 1:CAS:528:DC%2BD2sXhtVCit7jF (Pubitemid 47437463)
9. MG Roncarolo R Bacchetta C Bordignon S Narula MK Levings 2001 Type 1 T regulatory cells Immunol Rev 182 68 79 11722624 10.1034/j.1600-065X.2001. 1820105.x 1:CAS:528:DC%2BD3MXpt1eisLw%3D (Pubitemid 33070208)
10. TJ Curiel G Coukos L Zou X Alvarez P Cheng P Mottram M Evdemon-Hogan JR Conejo-Garcia L Zhang M Burow Y Zhu S Wei I Kryczek B Daniel A Gordon L Myers A Lackner ML Disis KL Knutson L Chen W Zou 2004 Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 942 949 15322536 10.1038/nm1093 1:CAS:528: DC%2BD2cXntFSkt7g%3D (Pubitemid 39273735)
11. 1 mediates suppression in the tumor microenvironment Clin Cancer Res 13 4345 4354 17671115 10.1158/1078-0432.CCR-07- 0472 1:CAS:528:DC%2BD2sXotlGqsLg%3D (Pubitemid 47219698)
12. AM Eggermont 2009 Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development Clin Cancer Res 15 6745 6747 19903779 10.1158/1078-0432.CCR-09-2377 1:CAS:528: DC%2BD1MXhtl2ktL7M
13. IJ DeVries C Castelli C Huygens JF Jacobs J Stockis B Schuler-Thurner GJ Adema CJ Punt L Rivoltini G Schuler PG Coulie SS Luca 2010 Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents Clin Cancer Res 17 1 8
14. TL Whiteside 2008 The tumor microenvironment and its role in promoting tumor growth Oncogene 27 5904 5912 18836471 10.1038/onc.2008.271 1:CAS:528:DC%2BD1cXhtF2msbbK
15. KM Dwyer S Deaglio W Gao D Friedman TB Strom SC Robson 2007 CD39 and control of cellular immune responses Purinergic Signal 3 171 180 18404431 10.1007/s11302-006-9050-y 1:CAS:528:DC%2BD2sXktVWis7g%3D
16. DW Hoskin JS Mader SJ Furlong DM Conrad J Blay 2008 Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review) Int J Oncol 32 527 535 18292929 1:CAS:528:DC%2BD1cXjs1Cmtbs%3D (Pubitemid 351330458)
17. G Borsellino M Kleinewietfeld D Di Mitri A Sternjak A Diamantini R Giometto S Hopner D Centonze G Bernardi ML Dell'Acqua PM Rossini L Battistini O Rotzschke K Falk 2007 Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression Blood 110 1225 1232 17449799 10.1182/blood-2006-12-064527 1:CAS:528:DC%2BD2sXptFKlsro%3D (Pubitemid 47281420)
18. S Deaglio KM Dwyer W Gao D Friedman A Usheva A Erat JF Chen K Enjyoji J Linden M Oukka VK Kuchroo TB Strom SC Robson 2007 Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression J Exp Med 204 1257 1265 17502665 10.1084/jem.20062512 1:CAS:528: DC%2BD2sXms1aktrs%3D (Pubitemid 46919862)
19. + T cell-mediated immunosuppression involves extracellular nucleotide metabolism Trends Immunol 29 99 102 18258482 10.1016/j.it.2007.12.005 1:CAS:528:DC%2BD1cXivVeisL8%3D
20. highFOXP3+ regulatory T cells J Biol Chem 285 7176 7186 19858205 10.1074/jbc.M109.047423 1:CAS:528:DC%2BC3cXisFaksrw%3D
21. +CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets J Immunol Meth 369 59 68 10.1016/j.jim.2011.04.004 1:CAS:528:DC%2BC3MXnsVymsbg%3D
22. C Bergmann L Strauss R Zeidler S Lang TL Whiteside 2007 Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment Cancer Immunol Immunother 56 1429 1442 17265021 10.1007/s00262-007-0280-9 (Pubitemid 47024702)
23. M Mandapathil MJ Szczepanski M Szajnik J Ren EK Jackson JT Johnson E Gorelik S Lang TL Whiteside 2010 Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells J Biol Chem 285 27571 27580 20558731 10.1074/jbc.M110.127100 1:CAS:528: DC%2BC3cXhtVOnsL7K
24. B Zhang 2010 CD73: a novel target for cancer immunotherapy Cancer Res 70 6407 6411 20682793 10.1158/0008-5472.CAN-10-1544 1:CAS:528:DC%2BC3cXhtVWqu7jN
25. 2 cooperation Expert Opin Biol Ther 11 1203 1214 21702720 10.1517/14712598.2011.581225 1:CAS:528:DC%2BC3MXpsFCqtrw%3D
26. SF Hausler I Montalban Del Barrio J Strohschein, et al. 2011 Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor2A-dependent suppression of T-cell function and NK cell cytotoxicity Cancer Immunol Immunother 60 10 1405 1418 21638125 10.1007/s00262-011-1040-4
27. S Yaqub K Tasken 2008 Role for the cAMP-protein kinase A signaling pathway in suppression of anti-tumor immune responses by regulatory T cells Crit Rev Oncog 14 57 77 19105570